A. C. MITA ET AL: "Phase II study of docetaxel with or without plinabulin (NPI-2358) in patients with non-small cell lung cancer (NSCLC).", JOURNAL OF CLINICAL ONCOLOGY, vol. 28, no. 15_suppl, 20 May 2010 (2010-05-20), pages 7592-7592, XP055394409, US ISSN: 0732-183X, DOI: 10.1200/jco.2010.28.15_suppl.7592 (B1)

AAVV: "Common Terminology Crteria for Adverse Events (CTCAE) v5.0", 27 November 2017 (2017-11-27), MedDRA (B1)

AAVV: "Febrile Neutropenia", JAMA ONCOLOGY, vol. 3, no. 12, 2017, page 251, (B1)

AAVV: "ICH Harmonised Tripartite Guideline: Nonclinical Exaluation for Anticancer Pharmaceuticals", 2009, International Conference on Harmonsation of Technical Requirements for Registration of Pharmaceuticals for Human Use vol. S9 (B1)

WO-A1-2005/077940 (B1)

MICHAEL MILLWARD ET AL.: 'phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel' THE JOURNAL OF NEW ANTICANCER AGENTS vol. 3, no. 30, 16 February 2011, pages 1065 - 1073, XP035052851 DOI: 10.1007/S10637-011-9642-4 (B1)

MILLWARD M. ET AL.: "Phase I trial of NPI-2358 (a novel vascular disrupting agent) plus docetaxel.", J. CLIN. ONCOL., vol. 27, no. 15S, May 2009 (2009-05), page 3571, (B1)

MILLWARD M. ET AL: "Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel", INVESTIGATIONAL NEW DRUGS ; THE JOURNAL OF NEW ANTICANCER AGENTS, KLUWER ACADEMIC PUBLISHERS, BO, vol. 30, no. 3, 16 February 2011 (2011-02-16), pages 1065-1073, XP035052851, (B1)

SATO I. ET AL.: "Prediction of docetaxel monotherapy-induced neutropenia on the monocyte parentage.", ONCOLOGY LETTERS, vol. 3, 2012, pages 860-864, (B1)

CRAWFORD J. ET AL.: "Myeloid Growth Factors, version 2.2017", J. NATL. COMPR. CANC. NETW., vol. 15, no. 12, 2017, pages 1520-1541, (B1)